Tectonic Advisors 13F: Adds $944K to Pfizer (PFE) Stake

Tectonic Advisors boosted its stake in Pfizer Inc. (NYSE: PFE) by 33,109 shares during the quarter, according to a Form 13F filing with the Securities and Exchange Commission on October 22, 2026. The filing showed the fund ending the period with 465,200 shares of the drug manufacturer valued at approximately $13.3 million. Pfizer shares closed at $30.42 on the day of the filing.

PFE Pfizer Inc.

$30.42 ▲ +27.07% year to date

1M 3M YTD

Daily close · Oct 22, 2026

What Changed in Tectonic Advisors's Pfizer Position

The fund expanded its holdings by 7.7%, lifting its previous stake of 432,091 shares up to 465,200 shares. The reported value of the position stood at $13,267,490 at the time of the filing.

Other Institutional Activity in Pfizer

Other large investors adjusted their positions in the drug maker around the same period. Symphony Financial grew its holdings by 58,554 shares, a 145.2% increase, ending with 98,868 shares worth about $2.8 million. Quilter trimmed its investment by 41,417 shares, down 6.2% to 621,511 shares valued at approximately $17.7 million. Fisher Asset Management, LLC lifted its holdings by 4,104,062 shares to reach 109,067,291 shares worth about $3.3 billion. Bank Of New York Mellon Corporation added 3,998,010 shares, a 7.4% increase that brought its total to 57,879,546 shares valued at roughly $1.7 billion.

Pfizer Inc. Stock Up 1.2%

Pfizer shares recently traded around $30.22, sitting below the $30.42 close recorded on October 22, 2026. The stock sits near its 52-week high of $30.44, well above its 52-week low of $23.62.

Recent Earnings

Pfizer reported trailing twelve-month revenue of $63.7 billion alongside basic earnings of $0.76 per share. The company is scheduled to release its next financial results on November 3, 2026.

Dividend

Pfizer pays an annual dividend rate of $1.72 per share, translating to a dividend yield of 5.65%.

Insider Buying and Selling at Pfizer Inc.

Company insiders executed several trades prior to the filing. Shantanu Narayen bought 2,059 shares at an average price of $24.29 on June 26, 2026, for a total value of $50,013.11. Jennifer B. Damico sold 3,278 shares at $25.40 for $83,261 on August 5, 2026. Ronald E. Blaylock purchased 39,231 shares at $25.46 on August 5, 2026, totaling $998,821. Chief Executive Officer Albert Bourla bought 38,000 shares at $26.34 on August 12, 2026, for a total value of $1,000,920.

Analysts Set New Price Targets

Wall Street firms updated their views on the stock ahead of the filing. On August 7, 2026, Guggenheim maintained its Buy rating while lowering its price target from $35.00 to $31.00. HSBC maintained a Hold rating and raised its target from $28.00 to $30.00 on September 10, 2026. Scotiabank maintained a Sector Outperform rating on October 6, 2026, lifting its target from $30.00 to $33.00. Cantor Fitzgerald maintained a Neutral rating on October 8, 2026, moving its target from $27.00 to $28.00. JP Morgan maintained a Neutral rating on October 9, 2026, while pushing its target from $28.00 to $30.00. Consensus analyst figures show a buy recommendation key across 26 opinions with a mean price target of $29.26.

About Pfizer

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide through its Biopharma, PC1, and Pfizer Ignite operating segments. Headquartered in New York, the company employs roughly 75,000 people.

Bottom Line

Investors will look toward Pfizer's upcoming earnings report on November 3, 2026, for further updates on the business. Institutional holdings reports provide a snapshot of past portfolio choices rather than real-time trading data.